Datapoint: Pfizer Scores Another Hemophilia Nod
Pfizer has secured its second FDA approval for a hemophilia treatment within six months. The latest approval is for Hympavzi, a subcutaneous injection designed for patients aged 12 and older with hemophilia A or B who have not developed antibodies to previous treatments. This new therapy aims to reduce bleeding episodes and offers a more convenient alternative to traditional intravenous infusions. With its $795,600 wholesale acquisition cost (WAC), Hympavzi is positioned as a cost-effective option compared to other treatments on the market. Pfizer’s Beqvez, a gene therapy that treats hemophilia B, was approved in April. So far, the drug holds covered status for 32% of all insured lives under the medical benefit, often with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 10/14/24